Cover

page
Back of cover page
DCVMN Annual Report 2012

Table of Contents

Message from the President......................................................................................................................................... 5
Message from the Secretariat....................................................................................................................................... 6
Our Values..................................................................................................................................................................... 7
Highlights 2012.............................................................................................................................................................. 8
DCVMN Annual General Meeting ................................................................................................................................. 13
Statement on governance.............................................................................................................................................. 16
Financial Statements..................................................................................................................................................... 18
Message from the President

Thirteen years after the establishment of DCVMN we move together into the Decade of Vaccines, with a new impetus for dynamism and synergy, to create greater impact and shape the global and regional vaccination landscape, while supporting national growth.

2012 was an eventful year for the Network. It started with the remarkable achievement of the declaration of India one year free of Polio, whereby many members have contributed significantly.

This year, the first ever hepatitis E vaccine was launched in China; 100 million people have been vaccinated in African belt countries against meningitis A; a cell based influenza vaccine completed phase 3 studies in Vietnam; novel HPV, typhoid and rotavirus vaccines are advancing into phase 3 trials, and several projects for developing Sabin IPV vaccines have been awarded to DCVMN members. All together these achievements highlight the innovative capacity of DCVMN members.

Furthermore, it was a year of growth with the incorporation of 12 new manufacturers that correspond to a third of our constituency of 37 members: the new members represent new networking opportunities for all. DCVMN is growing in size and importance and we are excited about future opportunities.

On the occasion of the DCVMN Annual General Meeting, held from 31st October to 2nd November, in Bali, Indonesia, members renewed their engagement and cooperation spirit in achieving the common mission of increasing the quality and availability of affordable vaccines for all people. On this occasion M. Suhardono, from BioFarma, was elected by members as new President, for a term of 2 years.

As we move forward into 2013 we are looking at further ways to develop our common activities, both through partners that share our mission and through innovative solutions to fortify the professional activities of all members and integrate the new members. We believe we have the flexibility to reach out at the same time as the capacity to generate cohesiveness.

On behalf of the Executive Committee, I would like to thank all members and each of you for the personal commitment, dedication, dynamism and loyalty that are the basis for strengthening the Network.

Akira Homma
DCVMN President
It has been a privilege and pleasure to join DCVMN. Having been in office for the past one year, I would like to thank you for your trust and support.

When meeting the members of DCVMN along the year I found inspiring women and men dedicated to protect children, families and communities against known and emerging infectious diseases, and striving to increase the quality and availability of vaccines for all.

Over the year 2012 together we reached out to a large number of manufacturers, and engaged with 12 new members, bringing new partners, new thinking, innovative technologies, and new opportunities for all. All DCVMN members responded constructively, with firm commitment and willingness to support our cause: supply vaccines to the people who need them most. We believe that supporting the manufacturers in developing countries will result in improving access towards universal vaccination.

We also welcomed five high profile new institutions as resource members: European Vaccine Initiative, Center for Vaccine Ethics and Policy, AERAS Foundation, International Vaccine Access Center and Coalition against Typhoid.

Sustainability has become the cornerstone of our industry, thus every effort we made was done with the aim of ensuring sustainability of members, partnerships, collaborations and our Network as a whole.

Finally, I would like to express my sincere appreciation for the guidance and oversight of our distinguished Executive Committee, brilliantly led by the President Dr. Akira Homma until November 2012, who together with the committee members play the all too important role of ensuring that our activities are performed at the pace for DCVMN to pursue its mission in a dynamic, productive and sustainable manner.

I look forward to continue building synergies and collaborating with you all.

Sonia Pagliusi
Executive Secretary
Our Values

**Equity**
We aim to maximizing access to vaccines by making them affordable to all people, and providing information and opportunities to all member companies from developing countries.

**Responsibility**
Each and all of our activities aim to support achieving our common mission.

**Accountability**
We strive to provide accurate reports and financial statements of our activities to all members.

**Transparency**
We foster a culture of good governance based on collegial decision making processes making information available to all involved parties.

**Respect**
Different opinions are welcome and respected.
Our 2012 journey has been characterized by efforts to intensify international operations, consolidate growth and generate value for members and partners. In driving the network forward our focus continue to be quality, innovation and sustainability of partnerships, based on communication platforms, on training and technology sharing.

**India free of Polio**

DCVMN wishes to congratulate all governmental organizations and engaged partners for the achievement of India completing one year without polio on 12 January 2012 - since its last case, in a 2-year-old girl, on 13 January 2011. DCVMN members Panacea, Haffkine, Bharat, and Biofarma are proud to have contributed to this achievement, in supplying billions of vaccine doses to Indian programmes, and are glad to be able to professionally support the Global Initiative to end Polio.
A MOU was signed on January 16\textsuperscript{th} to share office space at the Nyon Business Center and the Swiss association was constituted on February 15\textsuperscript{th} 2012, by a memorandum of association, and established as a not-for-profit international association of vaccine manufacturers according to articles 60 and following of the Swiss Civil Code. The international secretariat provides the Network with an independent platform, with freedom to operate internationally, liaise with members, governments, agencies, donors, civil society and other associations, and build the capacity to manage associative projects of common interest, to consolidate collaborations and eventually provide a platform for funding new activities. It also encourages participation of new companies and institutions in the Network activities, creating partnerships and leveraging resources.
At an extraordinary meeting on Decade of Vaccines collaboration (DOVc), 16-17 February, participants from DCVMN were present, and invited by DOVc secretariat to contribute with an article to the special issue to be published on DOVc partnerships. Together with executive members a summary of activities and achievements over the last decade was prepared and submitted. The impact of DCVMN members is especially tangible in the number of pentavalent (DTPHepBhib) doses available for childhood vaccination in poor countries, as well as the availability of OPV to end Polio. Furthermore, a DCVMN member made available a new vaccine against meningitis A, the first tailor-made vaccine for Africa, and the first ever Hepatitis E vaccine was launched by another member.
DCVMN Regional workshops - Beijing and New Delhi

In coordination and in collaboration with our member CNBG the first regional DCVMN workshop was organized in Beijing, on April 26th, to provide an opportunity for members and non-members from the Asia-Pacific region to share information on prequalification of vaccines, and explore potential partnerships. International as well as local speakers honored the audience in sharing knowledge, including speakers from PATH, CITICS and SGS. Around this workshop six manufacturers from China and three from Korea joined the Network.

A second workshop was held in Delhi, on October 5th, and was courteously chaired by Prof. Dr. K.K. Ganguly. At the workshop we had the opportunity to welcome our new members Haffkine from India, Pasteur Institute of Iran, and Incepta from Bangladesh. In addition to in-country members Bharat, BE, Indian Immunologicals, Panacea, Cadila, Serum Institute of India, also Razi Institute from Iran, Vacsera from Egypt and Queen Saovabha from Thailand participated. Experiences on prequalification of vaccines were shared, and featured speakers included representatives from Clinton Health Access Initiative (CHAI) among other partners.

Image credit: web.

*Health is real wealth...”  
Mahatma Ghandi*
The Webinar series is another initiative to provide information to members, and has been launched in August, to increase the awareness of best practices in manufacturing and management, providing updated information and references on new standards, regulatory procedures, and improved technologies to developing quality systems and processes. The monthly Webinars, based on an interactive audio-visual platform, are accessible for free to all DCVMN members workforce upon registration, from their PC or laptop anywhere in the world. Consisting of an online 45 minutes power-point presentation and a 15 minutes real-time Q&A session, with direct audio interface with the audience, the presentations also remain available for DCVMN members to consult any time later.

Fostering innovation

During 2012 several DCVMN members responded positively to calls from the global health community to engage in international initiatives to increase influenza vaccines manufacturing capacity in developing countries. A new cell based influenza pandemic vaccine completed phase three trials, in Vietnam. Further, manufacturers from India, China, Korea and Mexico committed their resources to engage in future collaborative development and production of safe and effective injected poliovirus vaccines (IPV) based on the Sabin strains, to ensure a sustainable supply of high quality vaccines to developing countries, to achieve and keep a polio free world.

We are grateful to SGS (www.sgs.com) for providing in-kind support for the platform to DCVMN.
On the occasion of the DCVMN Annual General Meeting, held from 30th October to 2nd November, in Bali, Indonesia, members renewed their engagement and cooperation spirit in achieving the common mission of increasing the quality and availability of affordable vaccines for all people.

More than hundred and forty delegates from 23 countries, representing 24 vaccine manufacturers and leaders of twenty major global health institutions including World Health Organization, PAHO, UNICEF, IVI, GAVI and governmental agencies such as NIH, USAID, NIBSC, HHS, RIVM, as well as respected non-governmental organizations including PATH, CHAI, AERAS, Hilleman Laboratories, Bill and Melinda Gates Foundation, gathered together to exchange information and ideas on how to jointly achieve our common goal of protecting people against known and emerging infectious diseases.

The scientific programme addressed priority areas in order to further the Network's mission, and included vaccine quality, influenza vaccine security, trends in international procurement and global access, innovation, strategic partnerships, and technology transfer.

A new strategic framework with focus on quality, access to new technology and sustainability of vaccine manufacturing was proposed by the Executive Committee, discussed, and approved by the assembly. The framework, drafted by a consultant, Dr. J. Milstien, outlines three main goals: 1) Strengthening the Network membership; 2) Accelerating the availability of member’s pipeline products for public health use; 3) securing long term funding for Network activities of common interest to members. Objectives for each goal were proposed and detailed activities to achieve them will be further elaborated and communicated. A new website and a new training initiative for DCVMN members, and fundraising proposals are being developed and will be implemented, in cooperation with international partners.
Delegates during the Annual General Meeting discussions: Dr. Homma (DCVMN President 2010-2012), Dr. Makhoana, Ms. Datla, Dr. Jadhav, Mr. Gao
Partnering with global organizations

DCVMN continues to actively engage with global partners, and serving the GAVI Alliance Board, to help fulfill its mission of saving children’s lives and protecting people’s health by increasing access to immunization in poor countries. It is also recognized that to accelerate access to vaccines it is especially relevant to engage with global industry in form of technology transfer initiatives. This has been the topic of a workshop at the GAVI Partners Forum held on December 7th, in Tanzania, and co-organized jointly with IFPMA and GAVI-CSOs constituency, representing the Civil Society Organizations at the Forum. Particularly we acknowledge the contribution of the Bangladesh Ministry of Health, and the contributions to the discussions and for efforts to generating an enabling environment for the vaccine industry in Bangladesh.

Engaging with corporate partners

To facilitate knowledge sharing and intensifying training opportunities for a skilled workforce, we organized the annual meeting and workshops held in developing countries together with partners. We are grateful to our corporate partners for the interest, support and collaborative spirit in helping fostering manufacturing excellence for the benefit of all people.
Statement on governance

The Executive Committee (EC) is responsible for ensuring that the vision and mission of the Network are pursued and that equity, accountability, transparency and respect are observed in the conduct of the operations and activities of DCVMN, maximizing the effectiveness when deploying common resources.

The Executive Committee is committed to foster a culture that emphasizes good governance and the application of good practices, in line with the statutes and bylaws of the association, while assuring the sovereignty of members, and control is exercised collegially based on joint decision making processes.

The Committee is currently composed of seven democratically elected representative members, with voting rights on matters to be decided upon, and one appointed executive secretary (non-voting) responsible for assisting the committee in the deliberations, serving as custodian of all records relating to the Association and responsible for overseeing the production of minutes of all Executive Committee meetings. The President is responsible for presiding all meetings and deliberations of the committee, leading the discussions and ensuring that all interests are heard and kept to the point; the Vice-President assists him and, in his absence, takes the role of chairing discussions. The Treasurer is responsible to supervise all financial transactions and disbursements, review, analyze and evaluate all matters relating to fiduciary control and compliance.

In addition, DCVMN representatives appointed as senior advisers to the Executive Committee serve at the GAVI board.

The Executive Committee receives, reviews, and approves regular reports from the Secretariat pertaining to the daily operations, brought to its attention for discussion and decision, as required.

All voting Executive Committee members act on a voluntary, non-remunerated basis.

Monthly reports are presented verbally at teleconferences, and quarterly written activities reports are presented to the Executive Committee, at the end of each quarter. Meetings and teleconferences are structured with pre-set agenda items and relevant documents are circulated to ensure the information is available where necessary to facilitate informed decision making.

In 2012 there were 2 face-to-face EC meetings held on February 15th and October 31st, and five teleconferences held on July 3rd, August 7th, September 4th, October 9th and December 11th. Participation of executive members is shown in the below table.

At the final quarter of the calendar/financial year the network activities and financial statements are presented to the executive committee and to the assembly of all members. Work plan and budget are then approved by the assembly.

Travel & Expenses Policy

Our internal policy is that when travelling on behalf of DCVMN the most economical, safe and efficient transportation is to be used. Excessive risk, excessive cost and luxury services, unnecessary or unjustified in the performance of official DCVMN business, are to be avoided. This guiding principle is the foundation for DCVMN Travel & Expenses Policy for staff and consultants.
<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Company</th>
<th>Attendance out of 7 EC meetings</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Dr. Akira Homma</td>
<td>Bio-Manguinhos (Fiocruz), Brazil</td>
<td>2/7</td>
</tr>
<tr>
<td>Member</td>
<td>Dr. Mahendra Suhardono</td>
<td>PT Bio Farma, Indonesia</td>
<td>3/7</td>
</tr>
<tr>
<td>Member</td>
<td>Dr. Harshavardhan</td>
<td>Bharat Biotech International Ltd, India</td>
<td>6/7</td>
</tr>
<tr>
<td>Member</td>
<td>Dr. Luciana Cerequeira Leite</td>
<td>Instituto Butantan, Brazil</td>
<td>6/7</td>
</tr>
<tr>
<td>Member</td>
<td>Dr. Morena Makhoana</td>
<td>The Biovac Institute, South Africa</td>
<td>5/7</td>
</tr>
<tr>
<td>Member</td>
<td>Mr. Steven Gao</td>
<td>Xiamen Innovax Biotech Co Ltd, China</td>
<td>4/7</td>
</tr>
<tr>
<td>Member</td>
<td>Dr. Yonglin Wu*</td>
<td>China National Biotec Group Company Ltd,</td>
<td>1/7</td>
</tr>
<tr>
<td>GAVI Board Representative</td>
<td>Ms. Mahima Datla</td>
<td>Biological E. Limited, India</td>
<td>5/7</td>
</tr>
<tr>
<td>GAVI Board Alternate</td>
<td>Dr. Suresh S Jadhav (non-voting)</td>
<td>Serum Institute of India, India</td>
<td>6/7</td>
</tr>
<tr>
<td>Executive Secretary</td>
<td>Dr. Sonia R Pagliusi (non-voting)</td>
<td>DCVMN International</td>
<td>7/7</td>
</tr>
</tbody>
</table>

*Dr. Younling Wu integrated the EC on 1st November 2012*

Minutes of all EC meetings held during the year are available to all members at the DCVMN International Secretariat upon request.

At the end of the financial year, the Network’s annual report and financial results are submitted to the Executive Committee for approval and publication.
**DCVMN INTERNATIONAL**

**STATEMENT OF INCOME AND EXPENDITURE FOR THE YEAR 2012**

*ENDED 31 DECEMBER 2012 – Unaudited - verified by Multi-Fiduciary Services, Geneva

**INCOME**

<table>
<thead>
<tr>
<th>Description</th>
<th>CHF</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership contributions received</td>
<td>202'060.30</td>
<td>221'000.00</td>
</tr>
<tr>
<td>Interests &amp; foreign exchange gain</td>
<td>2'646.15</td>
<td>2'894.17</td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td>204'706.45</td>
<td>223'894.17</td>
</tr>
</tbody>
</table>

**EXPENDITURE**

<table>
<thead>
<tr>
<th>Description</th>
<th>CHF</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wages &amp; social charges</td>
<td>89'778.55</td>
<td>98'193.74</td>
</tr>
<tr>
<td>Other administrative, insurances &amp; fees</td>
<td>11'241.19</td>
<td>12'294.80</td>
</tr>
<tr>
<td><strong>Total expenditures</strong></td>
<td>101'019.74</td>
<td>110'488.54</td>
</tr>
</tbody>
</table>

**BALANCE 2012 DCVMN International**

<table>
<thead>
<tr>
<th></th>
<th>CHF</th>
<th>USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>103'686.71</strong></td>
<td>113'405.63</td>
<td></td>
</tr>
</tbody>
</table>
Inside back cover
Back page